Your browser doesn't support javascript.
loading
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
Wang, Lei; Luo, Yongzhong; Ren, Shengxiang; Zhang, Zhihong; Xiong, Anwen; Su, Chunxia; Zhou, Jin; Yu, Xinmin; Hu, Yanping; Zhang, Xiaodong; Dong, Xiaorong; Meng, Shuyan; Wu, Fengying; Hou, Xiaoming; Dai, Yuanrong; Song, Weifeng; Li, Baiyong; Wang, Zhongmin Maxwell; Xia, Yu; Zhou, Caicun.
Afiliación
  • Wang L; Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Luo Y; The First Department of Thoracic Medicine, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
  • Ren S; Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Zhang Z; Department of Respiratory Oncology, Anhui Provincial Cancer Hospital, Hefei, People's Republic of China.
  • Xiong A; Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Su C; Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Zhou J; Department of Medical Oncology, Cancer Hospital of Sichuan Province, Chengdu, People's Republic of China.
  • Yu X; Department of Thoracic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, People's Republic of China.
  • Hu Y; Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
  • Zhang X; Department of Medical Oncology, Cancer Hospital of Nantong, Nantong, People's Republic of China.
  • Dong X; Cancer Center, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Meng S; Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Wu F; Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Hou X; Department of Medical Oncology, The First Hospital of Lanzhou University, Lanzhou, People's Republic of China.
  • Dai Y; Department of Respiratory Medicine, The 2nd School of Medicine, WMU/The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU, Wenzhou, People's Republic of China.
  • Song W; Akeso Biopharma, Inc., Zhongshan, People's Republic of China.
  • Li B; Akeso Biopharma, Inc., Zhongshan, People's Republic of China.
  • Wang ZM; Akeso Biopharma, Inc., Zhongshan, People's Republic of China.
  • Xia Y; Akeso Biopharma, Inc., Zhongshan, People's Republic of China.
  • Zhou C; Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China. Electronic address: caicunzhoudr@163.com.
J Thorac Oncol ; 19(3): 465-475, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37879536
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos